Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Xencor, Inc. (XNCR)

Pharmaceutical Preparations

http://www.xencor.com

Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

465 N. HALSTEAD ST., SUITE 200
PASADENA, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/03/2013

Market Cap

999,229,360

Shares Outstanding

60,880,000

Weighted SO

60,875,198

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

EWTX --.--%

KROS --.--%

GLUE --.--%

MLYS --.--%

ERAS --.--%

KURA --.--%

PTGX --.--%

MRUS --.--%

REPL --.--%

Beta

0.6890

Last Div

0.0000

Range

15.31-26.84

Chg

0.1300

Avg Vol

533046

Mkt Cap

999229360

Exch

NASDAQ

Country

US

Phone

626 305 5900

DCF Diff

10.9030

DCF

5.1270

Div Yield

0.0000

P/S

7.4783

EV Multiple

-6.4881

P/FV

1.7662

Div Yield %

0.0000

P/E

-5.6194

PEG

-0.5563

Payout

0.0000

Current Ratio

6.9243

Quick Ratio

6.9243

Cash Ratio

0.3842

DSO

60.2961

DIO

0.0000

Op Cycle

60.2961

DPO

465.1863

CCC

-404.8902

Gross Margin

0.9070

Op Margin

-1.2878

Pretax Margin

-1.3001

Net Margin

-1.3274

Eff Tax Rate

-0.0122

ROA

-0.2147

ROE

-0.2821

ROCE

-0.2306

NI/EBT

1.0210

EBT/EBIT

1.0096

EBIT/Rev

-1.2878

Debt Ratio

0.0248

D/E

0.0364

LT Debt/Cap

0.0214

Total Debt/Cap

0.0351

Int Coverage

-57356.3333

CF/Debt

1.6241

Equity Multi

1.4640

Rec Turnover

6.0535

Pay Turnover

0.7846

Inv Turnover

0.0000

FA Turnover

1.2923

Asset Turnover

0.1617

OCF/Share

0.5404

FCF/Share

0.3810

Cash/Share

8.2432

OCF/Sales

0.2494

FCF/OCF

0.7050

CF Coverage

1.6241

ST Coverage

4.0602

CapEx Coverage

3.3900

Div&CapEx Cov

3.3900

P/BV

1.7662

P/B

1.7662

P/S

7.4783

P/E

-5.6194

P/FCF

42.5240

P/OCF

29.9037

P/CF

29.9037

PEG

-0.5563

P/S

7.4783

EV Multiple

-6.4881

P/FV

1.7662

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 16, 04:30 [Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) Benzinga Jan 22, 11:00 Navigating 4 Analyst Ratings For Xencor MarketWatch Jan 06, 05:58 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Dec 26, 12:18 20 favorite small-cap stocks for 2024 among Wall Street analysts MarketWatch Dec 26, 12:18 20 favorite small-cap stocks for 2024 among Wall Street analysts MarketWatch Dec 26, 12:18 20 favorite small-cap stocks for 2024 among Wall Street analysts

Revenue Product Segmentation